when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

RISING · news · pharmadog

← back to RISING

News mentioning RISING

268 stories

Sep 29, 263 steps for taking on Novartis in radiopharma: Curium up firstbiospace

Sep 28, 26STAT+: It really is bleak out there, and list prices matterstat

Sep 28, 26Trump uses ‘contested’ power to cut more funding to HHSstat

Sep 28, 26Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Virfiercebiotech

Sep 25, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Sep 25, 26Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendilfiercebiotech

Sep 24, 26FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’biospace

Sep 23, 26China’s surging biotech sector represents both competition and lifeline for the USbiospace

Sep 22, 26‘It’s just survival now’: Why is almost a third of Boston’s life sciences lab space sitting vacant?fiercebiotech

Sep 22, 26Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030biospace

Sep 22, 26New federal autism committee head has financial ties to leucovorinstat

Sep 22, 26A hidden tradeoff in Trump’s drug pricing dealsbiopharma dive

Sep 21, 26STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer workstat

Sep 21, 26Are healthcare systems really ready for GLP-1s?biopharma dive

Sep 21, 26Addiction clinics see rising cases of kratom and 7-OH withdrawalstat

Sep 21, 26Skeptical about modern medicine? I know the feeling — and want to listenstat

Sep 18, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Sep 18, 26With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’fiercebiotech

Sep 15, 26FDA launches pilot program to speed up early US drug researchbiopharma dive

Sep 15, 26Businesses can now apply for NIH fundingstat

Sep 14, 26Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’biospace

Sep 14, 26Electra aims for $342M IPO to power inflammatory drug’s push through phase 3fiercebiotech

Sep 14, 26Psychedelic therapies ride wave of public favor into FDA hearingbiospace

Sep 13, 26GE HealthCare mulls $1B imaging chemicals maker deal: Financial Timesfiercebiotech

Sep 11, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Sep 11, 26Novartis’ board faces investor scrutiny after M&A misfires and R&D flopsbiospace

Sep 10, 26Lonza to build new US factory; Samsung Bio signs $262M contractendpoints

Sep 9, 26Mass. governor makes pre-election pitch to biotechs amid warning early-stage start-ups are 'dying'fiercebiotech

Sep 9, 26Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Marketsbiospace

Sep 9, 26Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stockfiercebiotech

← prevpage 3 of 9next →